Anhui Anke Biotechnology (Group)

What Anhui Anke Biotechnology (Group) does

Anhui Anke Biotechnology (Group) Co., Ltd. (安徽安科生物工程（集团）股份有限公司, szse:300009) is a China-based biopharmaceutical high-tech enterprise founded in 1994 and listed on the Shenzhen Stock Exchange ChiNext board on October 30, 2009, as one of the first batch of 28 ChiNext-listed companies. Headquartered in Hefei with operations across Hefei, Shanghai, Suzhou, Wuxi, Anqing, and Tongling, the company operates across eight business segments: biopharmaceuticals (gene engineering drugs, monoclonal antibodies, cell therapy), modern traditional Chinese medicine (under the 中华老字号 "余良卿" brand), chemical synthetic generics, diagnostic reagents (reproductive health, forensic DNA testing), DNA/genetic testing, peptide drug APIs (via Shanghai Suhu Yiming with EU CEP certifications), functional skincare, and functional nutrition products (安科优儿). Its core technology platforms span gene engineering, monoclonal antibodies, CAR-T cell therapy (via minority stake in Bosengi Medical — PA3-17), ADCs, peptide synthesis, and in vitro diagnostics. Marquee proprietary products include 安苏萌 (recombinant human growth hormone — China's pioneer domestic brand, 30+ years of market presence), 安赛汀 (trastuzumab biosimilar, approved 2023, Anhui's first antibody drug), 安达芬 (interferon alpha-2b — China's first domestically produced interferon), and a portfolio of peptide APIs (thymopentin, somatostatin, oxytocin, carbetocin, octreotide, atosiban) where somatostatin API has been designated as China's national standard reference material by 中检院 (NIFDC).

The company generates revenue through a sales-led GTM model operating a nationwide direct sales network covering all Chinese provinces, with regional offices organized by therapeutic area (pediatric endocrinology, reproductive health, oncology, anti-infection). Prescription biopharmaceuticals are sold primarily through hospital tenders and the national centralized procurement (集采) program, while consumer health products (functional skincare, nutritional supplements) are sold through retail pharmacies and e-commerce. Additional revenue streams include CDMO peptide API manufacturing services, exclusive distribution of partner products (e.g., 璟诺娃 long-acting FSH from Shanghai Baoji Pharma, under exclusive China distribution agreement signed 2025-07-09 with first shipment 2025-11-05), and licensing/royalty income. Customer segments are diversified across pediatric endocrinology, assisted reproductive medicine, HER2-positive oncology, forensic science/public security, anti-infection, and TCM consumer markets, with academic marketing through KOL networks and major medical conferences (ESMO, pediatric endocrinology conferences).

Name

Anhui Anke Biotechnology (Group)

Legal name

安徽安科生物工程（集团）股份有限公司

Website

https://ankebio.com

Company type

Public

Founded year

1994

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Anhui Anke Biotechnology (Group) is a China-based biopharmaceutical enterprise founded in 1994 (szse:300009) that develops, manufactures, and commercializes gene engineering drugs, monoclonal antibodies, peptide APIs, diagnostic reagents, TCM products, and consumer health products, serving Chinese hospitals, fertility clinics, forensic labs, and retail channels.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)

akta.pro secondary industries

Oncology & Hematology Pharmaceuticals (HLAIAAAC), Immunology & Inflammation Pharmaceuticals (HLAIAAAD), Biologic API/Drug Substance Manufacturing Services (HLAAAKAA), Respiratory & Allergy Pharmaceuticals (HLAIAAAH)

Keywords

• Recombinant biopharmaceuticals
• Gene engineering drugs
• Monoclonal antibody therapeutics
• Peptide API manufacturing
• In vitro diagnostic reagents

Headquarters

HQ city

Hefei

HQ country

China

HQ region

Asia

Offices13 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Biopharmaceutical Products: Revenue from proprietary biopharmaceutical products including growth hormones (安苏萌), monoclonal antibodies (安赛汀), interferon products, and therapeutic peptides distributed primarily to hospitals and clinics through direct sales.
2. Diagnostic Reagents: Revenue from in vitro diagnostic reagents for reproductive health (sperm function testing, AMH, leptin) and forensic DNA testing kits (AGCU STR fluorescent detection kits) sold to hospitals, clinics, and forensic laboratories.
3. Traditional Chinese Medicine: Revenue from modernized TCM products including medicated plasters (狗皮膏, 麝香壮骨膏), herbal granules, and oral preparations under the百年中华老字号 '余良卿' brand, sold through TCM hospitals and retail channels.
4. Chemical Generic Drugs: Revenue from generic chemical drugs including antibiotics (cephalosporins, amoxicillin), antivirals (adefovir, tenofovir), and cold/flu treatments sold to hospitals and pharmacies.
5. Functional Skincare & Nutritional Products: Revenue from consumer-facing functional skincare products (medical repair dressings, peptide skincare lines) and nutritional supplements (儿童 nutrition products under 安科优儿 brand) sold through retail and e-commerce channels.
6. Exclusive Distribution/Agency: Revenue from exclusive distribution rights for partner products including 晟诺娃 (long-acting FSH from Baoji Pharma), and licensing income from growth hormone products via 维昇药业 partnership.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Anhui Anke Biotechnology is a vertically integrated Chinese biopharmaceutical company that develops, manufactures, and commercializes recombinant gene engineering drugs (growth hormones, interferons, monoclonal antibodies), peptide active pharmaceutical ingredients, in vitro diagnostic reagents for reproductive health and forensic DNA testing, modernized traditional Chinese medicine, chemical generic drugs, and consumer health products (functional skincare and pediatric nutritional supplements). Its prescription biopharmaceutical products are sold primarily to hospitals and clinics through a nationwide direct sales network, while consumer-facing skincare and nutrition products are sold through retail pharmacies and e-commerce.

Differentiator

Problem solved

Functional benefit

Brands

• 安苏萌: Recombinant human growth hormone product line including injection powder and solution forms
• 安达芬
• 安赛汀
• 安科优儿
• 晟诺娃
• 余良卿
• 安科丽

Products and services

• Ansomone (安苏萌) Recombinant Human Growth Hormone for Injection Recombinant human growth hormone product for pediatric growth disorders (growth hormone deficiency, Noonan syndrome, SHOX gene defects, Turner syndrome, idiopathic short stature), adult short bowel syndrome, and burns. Sold primarily through hospital pharmacies and specialty pediatric endocrinology clinics.
• Ansomone (安苏萌) Human Growth Hormone Injection Solution Liquid formulation of recombinant human growth hormone for the same pediatric and adult indications as the powder form, offering dosing convenience.
• Ansaitin (安赛汀) Trastuzumab for Injection First domestically-produced trastuzumab biosimilar for HER2-positive metastatic breast cancer, early breast cancer, and metastatic gastric adenocarcinoma. Distributed to oncology hospitals and cancer treatment centers.
• AndaFen (安达芬) Human Interferon α2b Eye Drops China's first domestically-produced recombinant human interferon alpha-2b eye drop formulation, used for viral eye infections including herpes simplex keratitis.
• Atosiban Acetate Injection (醋酸阿托西班注射液) Peptide drug atosiban acetate injection used to delay preterm birth in pregnant women experiencing uterine contractions. Approved by NMPA in May 2025 and successfully included in national centralized procurement (集采) programs.
• Mengnuo Wa (暈諾娃) Long-Acting Recombinant FSH-CTP Fusion Protein Injection China's first long-acting follicle-stimulating hormone (FSH-CTP fusion protein) for controlled ovarian stimulation in IVF treatment, offering once-weekly dosing compared to daily short-acting FSH. Distributed exclusively in China by Anke Biotechnology under partnership with Shanghai Baoji Pharmaceutical.
• Yuliangqing (余良卿) Traditional Chinese Medicine Topical Analgesic Plasters Traditional Chinese Medicine external analgesic and orthopedic plasters and topical preparations under the national Time-honored Brand 余良卿, sold through TCM hospitals and retail pharmacies for pain relief, trauma, and orthopedic conditions.
• Yuliangqing TCM Oral Preparations Oral traditional Chinese medicine preparations under the 余良卿 brand including 肿节风颗粒 (Zhongjiefeng granules), 蛇胆川贝液 (Shedan Chuanbei Ye), 风寒咳嗽颗粒 (Fenghan Kesou granules), 酸枣仁合剂 (Suanzaoren mixture), and other cough, cold, insomnia, and lipid-lowering preparations.
• Generic Chemical Drug Oral Solid Dosage Portfolio

Quantifiable outcome

• HuA21 injection + trastuzumab + chemotherapy achieved 80.8% objective response rate (ORR) in HER2-positive advanced gastric/gastroesophageal junction adenocarcinoma
• +2 more outcomes

Named customers6 records

Segments6 records

Ideal customer profiles6 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Ten partnerships are on record, tiered core and minor.

• Shanghai Baoji Pharmaceutical Co., Ltd. (上海宝济药业股份有限公司)coreStrategic or Co-development Partner · 5 November 2025Anke Bio serves as the exclusive agent in China for 晟诺娃 (recombinant human FSH-CTP fusion protein injection), China's first long-acting follicle-stimulating hormone. Anke Bio made a cornerstone investment of approximately 112 million HKD (1.3% post-IPO shareholding) in Baoji Pharma's Hong Kong IPO in December 2025. First batch shipment occurred November 5, 2025.
• Visen Pharmaceuticals (维昇药业)coreStrategic or Co-development Partner · 25 August 2025Strategic partnership for distribution and co-promotion of pediatric endocrinology products including 隆培生长激素 (long-acting growth hormone, brand name 维臻高) and other growth hormone products. Both companies co-exhibited at the 25th Pediatric Endocrinology Genetics Metabolism Academic Conference (2026).
• Shanghai Suhu Yiming Pharmaceutical Co., Ltd. (上海苏豪逸明制药有限公司)coreOthersFully-owned subsidiary specializing in peptide API manufacturing. Products include thymopentin, thymalfasin, oxytocin, somatostatin, carbetocin, octreotide, and atosiban. Multiple APIs hold EU CEP certifications. Somatostatin API selected as national standard reference material by China 中检院 (NIFDC).
• Anhui Anke Yuliangqing Pharmaceutical Co., Ltd. (安徽安科余良卿药业有限公司)coreOthers控股东子公司;百年中华老字号 TCM company specializing in external analgesic plasters and traditional remedies. Certified as National Traditional Chinese Medicine Brand (中华老字号) by Ministry of Commerce in 2006. Products include狗皮膏, 麝香壮骨膏, and other medicated plasters.
• Anhui Anke Hengyi Pharmaceutical Co., Ltd. (安徽安科恒益药业有限公司)minorOthersFully-owned subsidiary manufacturing generic chemical drugs including antibiotics (cephalosporins, amoxicillin) and antivirals (tenofovir). Passed national centralized procurement and holds GMP certifications. Products participated in national集采 procurement.
• Wuxi Zhongde Meilian Biotechnology Co., Ltd. (无锡中德美联生物技术有限公司)minorOthersSubsidiary specializing in forensic DNA testing technology. Developer of AGCU fluorescent STR detection kits used in criminal investigation and national DNA databases. Kit for犬 17A STR received National Science and Technology Progress Award Second Class.
• Anhui Yugao Medical Management Co., Ltd. (安徽育高医疗管理有限公司)minorOthersSubsidiary operating medical management services related to the company's healthcare business.
• Hefei Hanke Microbow Biotechnology Co., Ltd. (合肥瀚科迈博生物技术有限公司)minorOthersSubsidiary involved in antibody and biological drug development.
• Anhui Xinhua Kun Biological Engineering Co., Ltd. (安徽鑫华坤生物工程有限公司)minorOthersSubsidiary focused on biological engineering and skincare product development.
• Jingze Bio-Pharmaceutical (Hefei) Co., Ltd. (景泽生物医药(合肥)股份有限公司)minorOthersAssociated company in the Hefei area focused on biopharmaceutical R&D and manufacturing.

Scale indicators6 records

Recent moves13 records

Expansion highlights7 records

Emerging players

• Innovent Biologics (信达生物): Chinese innovative biologics company with PD-1 inhibitor (sintilimab), biosimilars, and oncology pipeline. Comparable on biologic development focus and China commercial infrastructure, though more weighted to immuno-oncology than Anke's diversified portfolio.
• Junshi Biosciences (君实生物): Chinese biologics innovator with toripalimab (PD-1) and broader oncology pipeline. Comparable as a domestic biologics player with similar hospital-channel commercialization model, though more focused on immuno-oncology than Anke's therapeutic breadth.

Broad incumbents

• Novo Nordisk: Global leader in recombinant human growth hormone (Norditropin) and endocrine therapies including long-acting formulations. Direct therapeutic-area overlap on growth hormone, with global scale and ongoing next-generation endocrine product development relevant to Anke's long-acting GH pipeline strategy.
• Shanghai Pharmaceuticals (上海医药): China's largest pharmaceutical distributor with significant manufacturing and R&D operations. Comparable on distribution-driven business model and broad product portfolio, though much larger and more concentrated in distribution than Anke's R&D-intensive biopharma focus.
• Fosun Pharma (复星医药): Large diversified Chinese pharma with biopharma, diagnostics, medical devices, and healthcare services. Comparable breadth and Chinese market orientation, though substantially larger and more diversified than Anke across non-pharma healthcare segments.

Direct peers

• 3SBio (三生制药): Chinese biopharma with overlapping therapeutic areas including growth hormone (Eutropin), oncology biologics, and nephrology/immunology products. Comparable on biologics manufacturing scale, hospital sales-led model, and innovation pipeline focus on biosimilars and novel antibodies.
• Henlius (复宏汉霖): Chinese biosimilars and mAb developer with commercialized trastuzumab biosimilar (HLX01) approved in both China and EU. Direct competitor in HER2+ biosimilars and biosimilar manufacturing capability for oncology biologics, with similar hospital channel dynamics.
• Changchun High-Tech Industry (Jinsai Pharma): Owns GenScience (Jinsai), China's largest pediatric recombinant human growth hormone franchise and the most direct domestic competitor to Anke's Ansomone. Highly comparable on therapeutic area (pediatric endocrinology), commercial model (hospital sales), and product category (recombinant growth hormone).
• Livzon Group (丽珠集团): Diversified Chinese biopharma with direct overlap in reproductive health (Leuprorelin), chemical generic drugs, IVD diagnostics, and TCM. Comparable segment coverage mirrors Anke's 8-business model with similar hospital-channel commercial approach.

Others

• WuXi AppTec (药明康德): Global CDMO/CRO leader with peptide API capabilities relevant to Anke's Suhu Yiming peptide platform. Comparable as a peptide manufacturing services peer, and a potential strategic partner or competitor as Anke expands its peptide CDMO export franchise.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/anke_ltd
• Facebookfacebook.com/profile.php

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries15 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments3 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Anhui Anke Biotechnology (Group)